Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Portfolio Pulse from
Tharimmune, Inc. has announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic targeting PD-1 and VEGF receptors, using its proprietary EpiClick Technology.
March 04, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune, Inc. announced the development of HS1940, a novel biologic targeting PD-1 and VEGF receptors, expanding its product pipeline and showcasing its EpiClick Technology.
The announcement of HS1940, a new product leveraging Tharimmune's proprietary technology, is likely to positively impact the stock as it demonstrates innovation and potential for addressing unmet medical needs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100